<DOC>
	<DOCNO>NCT02726334</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( dose recommend Phase 2 study ) , safety , tolerability pharmacokinetic profile ( study movement drug within body , include absorption distribution ) study drug , BNC101 administer intravenously single agent combination chemotherapy patient metastatic colorectal cancer fail least 1 2 line chemotherapy .</brief_summary>
	<brief_title>A Phase I , Dose Escalation Study BNC101 Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Signed write Informed Consent 2 . Age &gt; 18 year 3 . Eastern Cooperative Oncology Group ( ECOG ) score 0 1 . 4 . Histologically cytologically confirm colorectal cancer patient fail least 2 line chemotherapy ( monotherapy treatment cohort ) least 1 line chemotherapy ( combination treatment cohort ) metastatic disease , opinion physician patient unreasonable try experimental therapy . Adjuvant FOLFOX within last 6 month consider line therapy . A maintenance strategy post 1st line treatment consider additional line therapy . 5 . Patients must accessible tumor lesion amenable biopsy would put patient treatment risk . Patients monotherapy escalation cohort 3 onwards , monotherapy expansion cohort , combination treatment patient , agree willing provide 2 serial tumor lesion biopsy ( minimum 2 fresh cores/punches prefer whenever possible ) . Biopsies liver metastasis , lieu primary tumor . The presence tumor tissue fresh biopsy certify trained pathologist use appropriate extemporaneous histology cytology procedure . Refer Appendix 6 biopsy procedure . 6 . All AEs prior chemotherapy , surgery , radiotherapy , must resolve Grade ≤ 1 . 7 . Measurable evaluable disease per RECIST version 1.1 . 8 . No known brain metastasis ( see also exclusion criterion No . 10 ) . 9 . Life expectancy least &gt; 12 week . 10 . Normal organ marrow function : 1 . Absolute neutrophil count ( ANC ) &gt; 1,500/mL without growth factor support past 14 day prior enrolment 2 . Platelets &gt; 100,000/mL without transfusion past 14 day prior enrolment 3 . Hemoglobin &gt; 9.0 g/dL Patients may transfuse receive erythropoietic treatment meet criterion 4 . Total bilirubin &lt; 1.5 x institutional upper limit normal ( ULN ) ( &lt; 2 x ULN subject Gilbert 's syndrome ) 5 . Serum albumin ≥ 3 g/dL . 11 . Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase , SGOT ) alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase , SGPT ) &lt; 2.5 x institutional ULN ( subject hepatic involvement &lt; 5 x institutional ULN associate elevated bilirubin ) . 12 . Alkaline phosphatase ( AlkPhos ) &gt; 2.5 x ULN , except patient document liver bone metastasis , &lt; 5 x ULN . 13 . For patient receive biopsy , prothrombin time ( PT ) activate partial thromboplastin time ( APTT ) /international normalize ratio ( INR ) within normal limit ( ± 15 % ) .. 14 . Creatinine &lt; 1.5 x institutional ULN OR Creatinine clearance &gt; 60 mL/min/1.73 m2 subject creatinine level institutional normal base CockroftGault glomerular filtration rate estimation : ( 140 age ) x ( weight kg ) x ( 0.85 female ) 72 x ( serum creatinine mg/dL ) ( NOTE : For patient Body Mass Index ( BMI ) &gt; 30 kg/m2 , lean body weight use instead ) 15 . No clinically significant abnormality urinalysis result ( obtained ≤ 14 day prior enrolment ) . 16 . No current recent ( within 3 month study drug administration ) gastrointestinal disease chronic intermittent diarrhea , disorder increase risk diarrhea , inflammatory bowel disease . Nonchronic condition ( e.g. , infectious diarrhea ) completely resolve least 2 week prior start study treatment allow . 17 . For female patient childbearing potential male patient partner childbearing potential , agreement ( patient and/or partner ) use highly effective form contraception ( e.g. , surgical sterilization , reliable barrier method , birth control pill , contraceptive hormone implant ) continue use 6 month last dose study drug . 18 . Women childbearing potential must negative serum pregnancy test ( βhCG ) within 72 hour prior first study drug administration . 1 . Inability comply study followup procedure ( include , limited : geographical administrative reason , plan vacation absences 7 consecutive day study ) . 2 . Women pregnant lactating . 3 . Colorectal cancer patient go receive 1st line therapy metastatic disease . 4 . Treatment chemotherapy , immunotherapy , biologic therapy , radiation therapy cancer therapy within 4 week initiation study treatment . Six week elapse prior chemotherapy treatment include nitrosoureas mitomycin C. 5 . Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior Day 1 Cycle 1 . 6 . Patients receive antibodybased therapy within 28 day 5 halflives agent , whichever longer . 7 . Major surgery , diagnostic surgery , within 6 week first study drug administration . 8 . Clinically detectable ( physical exam ) thirdspace fluid collection ( e.g. , ascites pleural effusion ) control drainage procedure prior study entry . 9 . Any uncontrolled medical psychiatric risk factor would contraindicate use impair ability patient provide inform consent , receive protocol therapy may impose excessive risk patient . 10 . Central nervous system ( CNS ) metastases , unless previously treat wellcontrolled least 3 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) . Patients display sign symptom CNS metastasis image CT magnetic resonance imaging ( MRI ) head . Should metastasis , include meningeal deposit detect , patient treat BNC101 . 11 . Current use medication may potential QTc prolongation ( refer Appendix 1 ) . If need use medication arises study , discussion approval sponsor would require . 12 . History allergy hypersensitivity Chinese Hamster Ovary cell product , compound BNC101 formulation , chemotherapy agent use study . 13 . Active uncontrolled bacterial , viral , fungal infection , require systemic therapy . 14 . Patient known infection human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C , alcoholic hepatitis , cirrhosis . 15 . Inability venipunctured and/or tolerate venous access . 16 . Second malignancy within 5 year prior enrolment , except negligible risk metastasis death , adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent . 17 . Active autoimmune disease control nonsteroidal antiinflammatory drug , inhale corticosteroid , equivalent &gt; 10 mg/day prednisone . 18 . Seizure disease require current anticonvulsant treatment . 19 . History inflammatory bowel disease ( active past ) active peptic ulcer disease . 20 . History chronic leukemia ( e.g. , chronic lymphocytic leukemia ) . 21 . History previous , whole abdomen radiation therapy ( total pelvic radiation therapy rectal cancer patient ) Grade 1 residual toxicity previous radiation therapy . NOTE : Patients previous standard , routine abdominopelvic radiotherapy eligible encompassed criterion , applies whole abdomen total pelvic radiotherapy . 22 . Patients high cardiovascular risk , include , limited coronary stenting previous 3 month myocardial infarction past year [ Patients New York Heart Association ( NYHA ) class I classification acceptable ] . 23 . Congenital acquire long QT syndrome . 24 . QTc prolongation define QTc interval great equal 450 msec baseline ; interval determination base mean value obtain 3 baseline ECGs obtain least 5 minute apart . 25 . Patients history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic</keyword>
</DOC>